Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates at a tertiary referral center

摘要

Background and AimAnti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at the end of induction.